The diagnostic accuracy of next-generation sequencing in advanced NSCLC.

ABSTRACT:

Background

Comprehensive genomic profiling is crucial for guiding treatment in advanced non-small cell lung cancer (NSCLC). However, tumor tissue-based targeted panel next-generation sequencing (TP-NGS) faces challenges, such as inadequate tissue sampling. Circulating tumor DNA (ctDNA) from peripheral blood has emerged as an alternative.

Methods

Participants with advanced NSCLC were enrolled in a Precision Oncology Program to enhance personalized treatments. TP-NGS was conducted using FoundationOne®CDx and FoundationOne®Liquid CDx. The study included an unpaired cohort and a paired cohort. We evaluated the impact of ctDNA tumor fraction (TF) on TP-NGS diagnostic accuracy, focusing on sensitivity as a key metric of efficacy.

Results

We prospectively analyzed data from

SUBMITTER: Ko EY 

PROVIDER: S-EPMC12409309 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature